Loading clinical trials...
Loading clinical trials...
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of Universal CAR-T Cell in Patients With CD19 and/or CD20 Positive Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Conditions
Interventions
Chimeric Antigen Receptor T Cells (CAR-T)
Locations
1
China
Shanghai Tongji Hospital
Shanghai, Shanghai Municipality, China
Start Date
July 10, 2025
Primary Completion Date
June 30, 2026
Completion Date
June 30, 2027
Last Updated
June 29, 2025
NCT06395103
NCT07523555
NCT07223021
NCT05674175
NCT07429461
NCT06785818
Lead Sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions